Translational, Bioethical, and Global Equity Challenges in the Deployment of Anti-HIV Biotherapies: From the Research Laboratory to the Most Affected Populations

This article confronts the most critical, non-biological frontier in the quest for an HIV cure: the ethical and logistical deployment of advanced biotherapies. As research advances toward sophisticated gene, cell, and immuno-engineering strategies, I argue that scientific feasibility alone is insufficient. This work critically examines the translational bottlenecks—from manufacturing scalability to regulatory fragmentation—and the profound bioethical dilemmas arising from deploying irreversible interventions in a non-fatal, managed disease. Most centrally, it analyzes the imminent risk of a two-tier global cure landscape and advocates for the principle of "equity-by-design"—the deliberate integration of accessibility, affordability, and justice into the core architecture of next-generation therapies. The success of an HIV cure will be measured not only in viral load, but in global health equity.